TNF and inflammatory bowel disease: What does seem likely, however, is a risk of developing hepatosplenic T cell lymphomas in children with inflammatory bowel disease (IBD) treated with a combination of azathioprine or 6-mercaptopurine (6-MP), and a monoclonal antibody (mAb) directed against TNF (e.g., infliximab or adalimumab) [13].